1
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, August 13, 1996: US05545569 (50 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are charac ...


2
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg & Woessner, December 5, 1995: US05472985 (39 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and prod ...


3
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, February 4, 1997: US05599844 (37 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and prod ...


4
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, August 31, 1999: US05945456 (29 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and prod ...


5
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, June 30, 1998: US05773479 (27 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and prod ...


6
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, December 8, 1998: US05847007 (12 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are charac ...


7
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, December 26, 2000: US06166090 (2 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are charac ...


8
Grainger David J, Metcalfe James C, Weissberg Peter L, Kemp Paul R: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. Neorx, May 8, 1996: EP0710116-A1

TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are charac ...


9
Grainger David J, Metcalfe James C, Weissberg Peter L, Kemp Paul R: Prevention et traitement de pathologies associees a la proliferation anormale de cellules de muscle lisse, Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. Neorx Corporation, Poniard Pharmaceuticals, GOUDREAU GAGE DUBUC, November 24, 1994: CA2162586

TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are charac ...


10
Grainger David J, Metcalfe James C, Weissberg Peter L, Kemp Paul R: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. Neorx Corporation, RAASCH Kevin W, November 24, 1994: WO/1994/026303

TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are charac ...